SITE005-0219

SITE005 (FRA) › SITE005-0219

SITE005-0219

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-05-22

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-07 (study day 101); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: UNKNOWN; onset 2022-12-18 (study day 22); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.